| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4c1bcc61e3e2e8772d1668124845e067 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-572 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-05 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 |
| filingDate |
2015-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2019-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74572ad3f7b0dbc8bd799c0c8260daf6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d941d8c8901b14bee92b85f6e4c52df |
| publicationDate |
2019-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10350260-B2 |
| titleOfInvention |
Compositions and methods for treating cancer and persistent viral infections |
| abstract |
The methods and compounds disclosed herein are useful in treating a subject having cancer or a viral infection by modulating the innate and adaptive immune systems typically by both inhibiting the function of inhibitory receptors and enhancing activity of activating receptors. Preferred therapeutic compositions comprise a carrier; at least one agent selected from the group consisting of: an anti-inflammatory agent, a cytotoxic T cell proliferation agent, or a NK cell proliferation agent; and a therapeutic peptide of the invention. In certain embodiments the compositions further include a second therapeutic peptide and/or an immunoglobulin admixed therewith in an amount sufficient to enhance passive immunoprotection in the subject. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019328826-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10821151-B2 |
| priorityDate |
2015-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |